United Kingdom

Quotient Sciences

Virtual Booth Transforming Drug Development with Science & Innovation.

United Kingdom

Contact Supplier

Virtual Booth

10th American DDF Summit

Attending

Request a Meeting Now

Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

Lead Product(s): GP1681

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: CytoAgents

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 28, 2020

Details:

Partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in 2020.

Sterling Pharma Solutions Limited

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate

Lead Product(s): WP1122

Therapeutic Area: Infections and Infectious Diseases Product Name: WP1122

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Moleculin Biotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 15, 2020

Details:

Moleculin Biotech has signed an agreement with Sterling Pharma for US production of WP1122 to support its expanded development efforts in preparation for submitting a request to the US FDA for Investigational New Drug status for WP1122 for the potential treatment of COVID-19.

Tiziana Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tiziana Life Sciences Announces Agreement STC Biologics for GMP Manufacturing

Lead Product(s): TZLS-501

Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-501

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: STC Biologics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 29, 2020

Details:

Tiziana's proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19

Treos Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine

Lead Product(s): PolyPEPI-SCoV-2

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

Treos Bio has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Advancing our Discovery of Novel Coronavirus-Neutralising Antibodies Against COVID-19

Lead Product(s): Monoclonal antibodies

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: academia

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 09, 2020

Details:

AstraZeneca has licensed coronavirus-neutralising antibodies from Vanderbilt University, US, and plans to advance a pair of these mAbs into clinical development as a potential combination therapy for the prevention and treatment of COVID-19.

Pneumagen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Pneumagen Announces £4m Fundraising and Commits to Clinical Trial Development for COVID-19

Lead Product(s): Carbohydrate binding modules

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Thairm Bio

Deal Size: $5.0 million Upfront Cash: Undisclosed

Deal Type: Funding May 27, 2020

Details:

The funding is directed towards the clinical development of Neumifil, a first-in-class Carbohydrate Binding Modules (mCBMs), generated using the Company’s proprietary GlycoTarge™ platform, for the prevention and treatment of COVID-19.